instruction
stringlengths 22
145
| input
stringclasses 1
value | answer
stringlengths 220
325
| text
stringlengths 382
597
|
|---|---|---|---|
The influence of disease stage at the start of treatment on the median PFS for No Maintenance. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The effect of concurrent health conditions on the median PFS for No Maintenance. | The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of No Maintenance from GIMEMA was 21.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
Median PFS for High-Dose Melphalan+Lenalidomide Maintenance? | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for High-Dose Melphalan+Lenalidomide Maintenance?
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
Comparison of the median PFS for High-Dose Melphalan+Lenalidomide Maintenance with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for High-Dose Melphalan+Lenalidomide Maintenance with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The impact of patient characteristics on the median PFS for High-Dose Melphalan+Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for High-Dose Melphalan+Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The role of genetic factors in the median PFS for High-Dose Melphalan+Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for High-Dose Melphalan+Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The influence of previous treatments on the median PFS for High-Dose Melphalan+Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for High-Dose Melphalan+Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The effect of dosage and administration frequency on the median PFS for High-Dose Melphalan+Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for High-Dose Melphalan+Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The correlation between the median PFS for High-Dose Melphalan+Lenalidomide Maintenance and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for High-Dose Melphalan+Lenalidomide Maintenance and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for High-Dose Melphalan+Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for High-Dose Melphalan+Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The role of supportive care in improving the median PFS for High-Dose Melphalan+Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for High-Dose Melphalan+Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for High-Dose Melphalan+Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for High-Dose Melphalan+Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The effect of concurrent health conditions on the median PFS for High-Dose Melphalan+Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for High-Dose Melphalan+Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+Lenalidomide Maintenance from GIMEMA was 54.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
Median PFS for High-Dose Melphalan+No Maintenance? | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for High-Dose Melphalan+No Maintenance?
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
Comparison of the median PFS for High-Dose Melphalan+No Maintenance with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for High-Dose Melphalan+No Maintenance with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The impact of patient characteristics on the median PFS for High-Dose Melphalan+No Maintenance. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for High-Dose Melphalan+No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The role of genetic factors in the median PFS for High-Dose Melphalan+No Maintenance. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for High-Dose Melphalan+No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The influence of previous treatments on the median PFS for High-Dose Melphalan+No Maintenance. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for High-Dose Melphalan+No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The effect of dosage and administration frequency on the median PFS for High-Dose Melphalan+No Maintenance. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for High-Dose Melphalan+No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The correlation between the median PFS for High-Dose Melphalan+No Maintenance and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for High-Dose Melphalan+No Maintenance and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for High-Dose Melphalan+No Maintenance. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for High-Dose Melphalan+No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The role of supportive care in improving the median PFS for High-Dose Melphalan+No Maintenance. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for High-Dose Melphalan+No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for High-Dose Melphalan+No Maintenance. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for High-Dose Melphalan+No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The effect of concurrent health conditions on the median PFS for High-Dose Melphalan+No Maintenance. | The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for High-Dose Melphalan+No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of High-Dose Melphalan+No Maintenance from GIMEMA was 37.4 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
Median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance? | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance?
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
Comparison of the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The impact of patient characteristics on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The role of genetic factors in the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The influence of previous treatments on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The correlation between the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The role of supportive care in improving the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The effect of concurrent health conditions on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +Lenalidomide Maintenance from GIMEMA was 34.2 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
Median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance? | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance?
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
Comparison of the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The impact of patient characteristics on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The role of genetic factors in the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The influence of previous treatments on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The correlation between the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The role of supportive care in improving the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
The effect of concurrent health conditions on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance. | The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance.
### Response:
The median progression-free survival (PFS) for the treatment combination of Melphalan+Prednisone+Lenalidomide (MPR) +No Maintenance from GIMEMA was 21.8 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/full/10.1056/nejmoa1402888)</sup> |
|
Median PFS for Idecabtagene Vicleucel (Ide-Cel)? | The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Idecabtagene Vicleucel (Ide-Cel)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
Comparison of the median PFS for Idecabtagene Vicleucel (Ide-Cel) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Idecabtagene Vicleucel (Ide-Cel) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The impact of patient characteristics on the median PFS for Idecabtagene Vicleucel (Ide-Cel). | The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Idecabtagene Vicleucel (Ide-Cel).
### Response:
The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The role of genetic factors in the median PFS for Idecabtagene Vicleucel (Ide-Cel). | The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Idecabtagene Vicleucel (Ide-Cel).
### Response:
The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The influence of previous treatments on the median PFS for Idecabtagene Vicleucel (Ide-Cel). | The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Idecabtagene Vicleucel (Ide-Cel).
### Response:
The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Idecabtagene Vicleucel (Ide-Cel). | The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Idecabtagene Vicleucel (Ide-Cel).
### Response:
The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The correlation between the median PFS for Idecabtagene Vicleucel (Ide-Cel) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Idecabtagene Vicleucel (Ide-Cel) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Idecabtagene Vicleucel (Ide-Cel). | The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Idecabtagene Vicleucel (Ide-Cel).
### Response:
The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The role of supportive care in improving the median PFS for Idecabtagene Vicleucel (Ide-Cel). | The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Idecabtagene Vicleucel (Ide-Cel).
### Response:
The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Idecabtagene Vicleucel (Ide-Cel). | The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Idecabtagene Vicleucel (Ide-Cel).
### Response:
The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The effect of concurrent health conditions on the median PFS for Idecabtagene Vicleucel (Ide-Cel). | The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Idecabtagene Vicleucel (Ide-Cel).
### Response:
The median progression-free survival (PFS) for the treatment combination of Idecabtagene Vicleucel (Ide-Cel) from KarMMa-3 was 13.3 months with a 95% Confidence Interval (CI) of (11.8, 16.1) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
Median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;? | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;?
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
Comparison of the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ; with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ; with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The impact of patient characteristics on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The role of genetic factors in the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The influence of previous treatments on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The correlation between the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ; and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ; and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The role of supportive care in improving the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The effect of concurrent health conditions on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Pomalidomide+Dexamethasone (DPd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
Median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ;? | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ;?
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
Comparison of the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ; with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ; with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The impact of patient characteristics on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ;. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The role of genetic factors in the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ;. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The influence of previous treatments on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ;. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ;. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The correlation between the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ; and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ; and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ;. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The role of supportive care in improving the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ;. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ;. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The effect of concurrent health conditions on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ;. | The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Daratumumab+Bortezomib+Dexamethasone (DVd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Daratumumab+Bortezomib+Dexamethasone (DVd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
Median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ;? | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ;?
### Response:
The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
Comparison of the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ; with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ; with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The impact of patient characteristics on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ;. | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The role of genetic factors in the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ;. | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The influence of previous treatments on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ;. | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ;. | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The correlation between the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ; and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ; and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ;. | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The role of supportive care in improving the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ;. | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ;. | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The effect of concurrent health conditions on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ;. | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
Median PFS for Carfilzomib+Dexamethasone (Kd) ;? | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Carfilzomib+Dexamethasone (Kd) ;?
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
Comparison of the median PFS for Carfilzomib+Dexamethasone (Kd) ; with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Carfilzomib+Dexamethasone (Kd) ; with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The impact of patient characteristics on the median PFS for Carfilzomib+Dexamethasone (Kd) ;. | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Carfilzomib+Dexamethasone (Kd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The role of genetic factors in the median PFS for Carfilzomib+Dexamethasone (Kd) ;. | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Carfilzomib+Dexamethasone (Kd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The influence of previous treatments on the median PFS for Carfilzomib+Dexamethasone (Kd) ;. | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Carfilzomib+Dexamethasone (Kd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The effect of dosage and administration frequency on the median PFS for Carfilzomib+Dexamethasone (Kd) ;. | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Carfilzomib+Dexamethasone (Kd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The correlation between the median PFS for Carfilzomib+Dexamethasone (Kd) ; and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Carfilzomib+Dexamethasone (Kd) ; and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The impact of side effects and adverse reactions on the median PFS for Carfilzomib+Dexamethasone (Kd) ;. | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Carfilzomib+Dexamethasone (Kd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The role of supportive care in improving the median PFS for Carfilzomib+Dexamethasone (Kd) ;. | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Carfilzomib+Dexamethasone (Kd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
|
The influence of disease stage at the start of treatment on the median PFS for Carfilzomib+Dexamethasone (Kd) ;. | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Carfilzomib+Dexamethasone (Kd) ;.
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) ; from KarMMa-3 was 4.4 months with a 95% Confidence Interval (CI) of (3.4, 5.9) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa2213614)</sup> |
Subsets and Splits